Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
SOUTH PLAINFIELD, N.J., Sept. 21, 2016 -- Molecular Diagnostics company, Admera Health, (www.admerahealth.com) today announced that its PGxOne™ Plus pharmacogenomics test has been updated to include 25 additional genes, bringing the total number of genes covered to 50.
PGxOne™ Plus results help predict how patients will respond to drug therapy for several therapeutic areas including psychiatry, pain management and cardiology. Leveraging Next Generation Sequencing (NGS) technology, this expanded 50 gene panel interrogates nearly 200 different variants and provides recommendations for over 220 associated drugs. The recommendations include considering alternatives when specific drugs should be avoided, dosage adjustment information when available, use with caution, and normal response expected. The PGxOne™ Plus report also provides information related to drug-to-drug, drug-to-food, drug-to-alcohol and drug-to-laboratory test interactions that are relevant to a patient’s current medications. Thus, test results offer physicians a valuable tool for guiding effective treatment decisions and potentially reducing trial-and-error treatment selection and adverse drug events.
“With this product update we have doubled the number of genes on what was already the most comprehensive pharmacogenomics test on the market. However, only gene variants that have strong clinical evidence associated with drug metabolism, absorption and activity are included in the panel,” stated Guanghui Hu, PhD, President and CEO of Admera.
Dr. Hu went on to elaborate, “As pharmacogenomics testing becomes the standard of care, it is clear that Admera Health is emerging as the leader in this field.”
In addition to pharmacogenomics testing, Admera Health provides genetic testing for the risk assessment and diagnosis of inherited cardiovascular diseases and cancer tumor profiling to guide selection of targeted therapies.
About Admera Health
Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
